New shot aims to free hepatitis b patients from daily pills

NCT ID NCT07137910

Recruiting now Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetectable 24 weeks after stopping therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AHB-137 injection
What this could lead to: If successful, this could lead to a new treatment that helps people with chronic hepatitis B stop taking daily antiviral pills while keeping the virus under control.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AusperBio Investigational Site
RECRUITING

Beijing, Beijing Municipality, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Jilin City, Changchun, China

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, China
AusperBio Investigational Site
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Xiamen, Fujian, China

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Guangzhou, Guangdong, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Shenzhen, Guangdong, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Nanning, Guangxi, China

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Zhengzhou, Henan, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Changzhou, Jiangsu, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Chengdu, Sichuan, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.